The COVAX initiative, worth $18 billion, is planning to administer COVID-19 vaccines to two-thirds of the world’s population by 2021. Sanofi and GalxoSmithKline have agreed to supply 2 million doses to the World Health Organization (WHO) of a vaccine they have been studying since early September. The companies hope to enter Phase III and eventually receive U.S. Food and Drug Administration (FDA) approval of the drug come 2021.

More on: